
Positive data on BOTRESO and MCS-8 highlight dual advances in prostate health
Clinical data from Jyong Biotech’s investigational candidates in benign prostatic hyperplasia (BPH) and prostate cancer were recently shared at the 22nd Urological Association of Asia (UAA) Congress, the company announced in a news release.1 The …